Cancer
Malignant Ovarian Neoplasm
CI-CAN-00003205Explore in graph →
Top-level685 active trials5 approved drugs83 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003205Explore in graph →
Clinical trials
3,087 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (437)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00002526 | Chemotherapy in Treating Patients With Advanced Sarcoma | completed | Phase 2 | 20 | Swiss Cancer InstituteOTHER | 1 | May 15, 2012 | clinicaltrials |
| NCT01584115 | Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA) | unknown | Phase 1 / Phase 2 | 15 | Instituto de Investigação em ImunologiaOTHER | 1 | Apr 25, 2012 | clinicaltrials |
| NCT00505661 | Letrozole in Patients With Ovarian Tumors | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 18, 2012 | clinicaltrials |
| NCT00407563 | Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer | completed | Phase 2 | 48 | Accelerated Community Oncology Research NetworkOTHER | 1 | Apr 5, 2012 | clinicaltrials |
| NCT01570582 | A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | unknown | Phase 2 | 314 | Korean Gynecologic Oncology GroupOTHER | 1 | Apr 4, 2012 | clinicaltrials |
| NCT00561795 | Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors | completed | Phase 2 | 12 | GlaxoSmithKlineINDUSTRY | 2 | Mar 22, 2012 | clinicaltrials |
| NCT00064311 | Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation | completed | Phase 1 / Phase 2 | — | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 8, 2012 | clinicaltrials |
| NCT00607607 | A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer | completed | Phase 2 | 44 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | Jan 20, 2012 | clinicaltrials |
| NCT00020696 | Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 4 | Jan 10, 2012 | clinicaltrials |
| NCT00569257 | Antitumoral Activity and Safety of AEZS-108 in Women With LHRH Receptor Positive Gynecological Tumors | completed | Phase 2 | 85 | AEterna ZentarisINDUSTRY | 2 | Dec 13, 2011 | clinicaltrials |
| NCT00003887 | Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation | completed | Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 30, 2011 | clinicaltrials |
| NCT00418574 | Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients(MIMOSA) | terminated | Phase 2 / Phase 3 | 888 | Menarini GroupINDUSTRY | 9 | Nov 24, 2011 | clinicaltrials |
| NCT00926107 | Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse | terminated | Phase 2 | 9 | Hellenic Cooperative Oncology GroupOTHER | 1 | Nov 10, 2011 | clinicaltrials |
| NCT00466986 | Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer | completed | Phase 2 | 40 | Southeastern Gynecologic OncologyOTHER | 1 | Oct 12, 2011 | clinicaltrials |
| NCT00429559 | Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma | completed | Phase 1 / Phase 2 | 31 | Hellenic Oncology Research GroupOTHER | 1 | Jul 22, 2011 | clinicaltrials |
| NCT00593580 | Bone Health in Gynecologic Cancers-does FOSAVANCE Help?(FOSAVANCE) | completed | Phase 2 | 60 | British Columbia Cancer AgencyOTHER | 1 | Jun 29, 2011 | clinicaltrials |
| NCT00004177 | Radiolabeled Monoclonal Antibody Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory or Recurrent Ovarian Epithelial Cancer | completed | Phase 1 / Phase 2 | 15 | Garden State Cancer Center at the Center for Molecular Medicine and ImmunologyOTHER | 1 | Jun 22, 2011 | clinicaltrials |
| NCT00489359 | Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 86 | Eli Lilly and CompanyINDUSTRY | 5 | Jun 16, 2011 | clinicaltrials |
| NCT00750386 | Paclitaxel and Carboplatin Combination as 1st Line Treatment in Ovarian Carcinomas | completed | Phase 1 / Phase 2 | 50 | Hellenic Oncology Research GroupOTHER | 1 | May 23, 2011 | clinicaltrials |
| NCT00003160 | Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum | unknown | Phase 2 | 100 | TheradexINDUSTRY | 1 | Apr 20, 2011 | clinicaltrials |
| NCT00005049 | Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer | completed | Phase 2 | 45 | NYU Langone HealthOTHER | 1 | Apr 6, 2011 | clinicaltrials |
| NCT00004083 | Liposomal Cisplatin in Treating Patients With Recurrent Ovarian Cancer | completed | Phase 2 | — | NYU Langone HealthOTHER | 1 | Mar 28, 2011 | clinicaltrials |
| NCT00003297 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Cancer | completed | Phase 1 / Phase 2 | 50 | Georgetown UniversityOTHER | 1 | Mar 24, 2011 | clinicaltrials |
| NCT00189566 | Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse | completed | Phase 2 | 165 | ARCAGY/ GINECO GROUPOTHER | 1 | Feb 25, 2011 | clinicaltrials |
| NCT00517621 | Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire | completed | Phase 2 | 100 | ARCAGY/ GINECO GROUPOTHER | 1 | Feb 25, 2011 | clinicaltrials |
| NCT00844506 | p53 Synthetic Long Peptides Vaccine With Cyclophosphamide for Ovarian Cancer(ISA-P53-CTX) | completed | Phase 2 | 19 | University Medical Center GroningenOTHER | 1 | Feb 25, 2011 | clinicaltrials |
| NCT00316407 | Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients | completed | Phase 1 / Phase 2 | 30 | Swedish Medical CenterOTHER | 1 | Feb 18, 2011 | clinicaltrials |
| NCT00003269 | Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors | completed | Phase 2 | 20 | Scripps HealthOTHER | 1 | Jan 10, 2011 | clinicaltrials |
| NCT00097409 | Ispinesib In Subjects With Platinum-Taxane-Refractory Or Resistant Relapsed Ovarian Cancer | completed | Phase 2 | 35 | GlaxoSmithKlineINDUSTRY | 1 | Oct 4, 2010 | clinicaltrials |
| NCT00002508 | Combination Chemotherapy Followed by Bone Marrow or Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Germ Cell Tumors | completed | Phase 1 / Phase 2 | — | Temple UniversityOTHER | 1 | Oct 1, 2010 | clinicaltrials |
| NCT00217529 | Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer | completed | Phase 1 / Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 21, 2010 | clinicaltrials |
| NCT00217555 | Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 21, 2010 | clinicaltrials |
| NCT00217568 | Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer | completed | Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 21, 2010 | clinicaltrials |
| NCT01180504 | Consolidation Whole Abdominal Intensity-Modulated Radiation Therapy (IMRT) in Advanced Ovarian Cancer(OVAR-IMRT-02) | unknown | Phase 2 | 36 | University Hospital HeidelbergOTHER | 1 | Aug 12, 2010 | clinicaltrials |
| NCT00109993 | Campath-1H + FK506 and Methylprednisolone for GVHD | completed | Phase 2 | 34 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 11, 2010 | clinicaltrials |
| NCT00410657 | Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant | completed | Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | May 14, 2010 | clinicaltrials |
| NCT00082212 | A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma | terminated | Phase 2 | 25 | Eli Lilly and CompanyINDUSTRY | 1 | Apr 9, 2010 | clinicaltrials |
| NCT00063401 | Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer | completed | Phase 2 | 39 | Eli Lilly and CompanyINDUSTRY | 1 | Apr 8, 2010 | clinicaltrials |
| NCT00004157 | Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors | completed | Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 2, 2010 | clinicaltrials |
| NCT00010283 | Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon | completed | Phase 1 / Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 2, 2010 | clinicaltrials |
| NCT00261027 | Aromasin (Exemestane) in Patients With Recurrent or Refractory Stage II - IV Epithelial Ovarian Cancer | completed | Phase 2 | 30 | Ottawa Hospital Research InstituteOTHER | 1 | Mar 2, 2010 | clinicaltrials |
| NCT00291837 | CT-2106 for the Second Line Treatment of Ovarian Cancer | completed | Phase 2 | 40 | CTI BioPharmaINDUSTRY | 3 | Feb 26, 2010 | clinicaltrials |
| NCT00277290 | Study of XL999 in Patients With Previously Treated Ovarian Cancer | terminated | Phase 2 | 24 | Symphony Evolution, Inc.INDUSTRY | 1 | Feb 22, 2010 | clinicaltrials |
| NCT00239980 | Fragmin in Ovarian Cancer: Utility on Survival (FOCUS) | completed | Phase 2 | 77 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Feb 3, 2010 | clinicaltrials |
| NCT00461786 | A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer | completed | Phase 2 | 51 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 4, 2009 | clinicaltrials |
| NCT00905658 | Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer | unknown | Phase 2 | 120 | Centre Oscar LambretOTHER | 1 | Jul 29, 2009 | clinicaltrials |
| NCT00610792 | Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens | withdrawn | Phase 2 | 91 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Jul 14, 2009 | clinicaltrials |
| NCT00034151 | Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer | completed | Phase 2 | 52 | Achieve Life SciencesINDUSTRY | 0 | Jun 4, 2009 | clinicaltrials |
| NCT00003135 | Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer | unknown | Phase 2 | 34 | The University of Texas Health Science Center, HoustonOTHER | 1 | Apr 30, 2009 | clinicaltrials |
Data updated 23 days agoSource updated May 15, 2012source: clinicaltrials